BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 906404)

  • 21. [Immunotherapy of malignant melanomas].
    Macher E
    Haematol Blood Transfus; 1978; 21():285-91. PubMed ID: 738638
    [No Abstract]   [Full Text] [Related]  

  • 22. Experience with BCG adjuvant immunotherapy in stage II malignant melanoma.
    Peter HH; Deutschmann EM; Schultheis W; Deicher H
    Dev Biol Stand; 1977 Apr 13-15; 38():537-40. PubMed ID: 344106
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Immunology of melanoma].
    Vanwijck R; Bernheim JL; Lejeune FJ
    Acta Chir Belg; 1974 Mar; 73(2):135-88. PubMed ID: 4615541
    [No Abstract]   [Full Text] [Related]  

  • 24. Effects of BCG and Corynebacterium parvum on immune reactivity in melanoma patients.
    Thatcher N; Crowther D
    Dev Biol Stand; 1977 Apr 13-15; 38():449-53. PubMed ID: 608536
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Possibilities of immunotherapy in malignant melanoma].
    Lewis MG
    Hautarzt; 1978 Dec; 29(12):619-24. PubMed ID: 363650
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [A malignus melanoma immunterápiájának lehetoségei].
    Ladányi A
    Magy Onkol; 2003; 47(1):113-7. PubMed ID: 12704464
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Immunological aspects of melanoma].
    Sjögren H
    Lakartidningen; 1976 Feb; 73(7):528-30. PubMed ID: 1250045
    [No Abstract]   [Full Text] [Related]  

  • 28. Melanoma-reactive human cytotoxic T lymphocytes derived from skin biopsies of delayed-type hypersensitivity reactions induced by injection of an autologous melanoma cell line.
    Waanders GA; Rimoldi D; Liénard D; Carrel S; Lejeune F; Dietrich PY; Cerottini JC; Romero P
    Clin Cancer Res; 1997 May; 3(5):685-96. PubMed ID: 9815737
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Correlation of the level of humoral cytotoxins and delayed hypersensitivity skin reactions with survival of patients with melanoma of the skin].
    Korosteleva TA; Vagner RI; Veresova OV; Potapenkova LS
    Vopr Onkol; 1983; 29(4):38-40. PubMed ID: 6858049
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Polyvalent melanoma cell vaccine induces delayed-type hypersensitivity and in vitro cellular immune response.
    Barth A; Hoon DS; Foshag LJ; Nizze JA; Famatiga E; Okun E; Morton DL
    Cancer Res; 1994 Jul; 54(13):3342-5. PubMed ID: 8012946
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of chemotherapy and immunotherapy on tumor-specific immunity in melanoma.
    Mitchell MS; Mokyr MB; Davis JM
    J Clin Invest; 1977 Jun; 59(6):1017-26. PubMed ID: 863999
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intralesional BCG application in malignant melanoma.
    Sopková B; Kolár V
    Neoplasma; 1976; 23(4):421-6. PubMed ID: 794745
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cancer immunotherapy.
    Richman SP; Gutterman JU; Hersh EM
    Can Med Assoc J; 1979 Feb; 120(3):322-4, 329. PubMed ID: 371776
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Activity of 2,4 dinitrochlorbenzene skin tests during the course of immunotherapy of malignant melanomas].
    Richter J; Duchková H; Kubíková M
    Cas Lek Cesk; 1975 Sep; 114(39):1201-3. PubMed ID: 1182748
    [No Abstract]   [Full Text] [Related]  

  • 35. Histologic changes in the human skin melanoma after intratumorous treatment with BCG.
    Svejda J; Mechl Z; Sopková B; Foukal T
    Neoplasma; 1979; 26(2):215-21. PubMed ID: 471128
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunologic effects of BCG in patients with malignant melanoma: specific evidence for stimulation of the 'secondary' immune response.
    Chess L; Bock GN; Ungaro PC; Buchholz DH; Mardiney MR
    J Natl Cancer Inst; 1973 Jul; 51(1):57-65. PubMed ID: 4720886
    [No Abstract]   [Full Text] [Related]  

  • 37. Kinetics of the immune response and regression of metastatic lesions following development of humoral anti-high molecular weight-melanoma associated antigen immunity in three patients with advanced malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2-23.
    Mittelman A; Chen ZJ; Liu CC; Hirai S; Ferrone S
    Cancer Res; 1994 Jan; 54(2):415-21. PubMed ID: 8275478
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical and immunological significance of human melanoma cytotoxic antibody.
    Bodurtha AJ; Chee DO; Laucius JF; Mastrangelo MJ; Prehn RT
    Cancer Res; 1975 Jan; 35(1):189-93. PubMed ID: 1109788
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Immunology and immunotherapy of lung cancer--experimental and clinical investigations (author's transl)].
    Micksche VM
    Wien Klin Wochenschr Suppl; 1978; 90():1-28. PubMed ID: 362733
    [No Abstract]   [Full Text] [Related]  

  • 40. [Immune reactions in assessing the disease prognosis in soft tissue sarcomas].
    Klimenkov AA; Kadagidze ZG; Gladikov IuV
    Vopr Onkol; 1979; 25(1):3-8. PubMed ID: 425395
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.